Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 2

OvaScience Co-Founder Recognized in Boston Globe 100’s “The Innovators” Feature

Company also named among Boston’s 50 on Fire OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that OvaScience Co-Founder Jonathan L. Tilly, Ph.D., has been named to The Boston Globe’s 2013 “

Lundbeck and Takeda's Brintellix shows positive results in Ph III major depression study

Danish CNS specialist Lundbeck (LUND: DC) and partner Takeda Pharmaceutical (TYO: 4502), Japan's largest drugmaker, are presenting new data on four pivotal studies on Brintellix (vortioxetine), a novel investigational drug, at the 2013 Annual Meeting...

Covidien Receives FDA 510(k) Clearance for Nellcor™ Pulse Oximetry Motion Claims

Nellcor pulse oximeters only FDA 510(k)-cleared oximeters compliant with ISO 80601-2-61 Covidien, a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced that its Nellcor™ pulse oximetry portfolio, which is used to measure arterial oxygen saturation, has rece...

DVS Sciences CyTOF® Mass Cytometer Featured in Paper Selected to Receive the Cytometry A 2012 Best Paper Award

DVS Sciences, Inc., a privately held innovator of novel multi-parameter single-cell analyzers and reagents for biological research technology, today announced that its CyTOF® Mass Cytometer was used in an award winning paper. The paper, Single-Cell Mass Cytometry Adapted to Measurements of the Cell Cycle, published in Cytometry Part A (81A:552-56...

Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain

Recent studies released by the Southern University of Denmark explain how the same P.acnes bacteria that causes acne is now known to cause lower back pain. Adult acne treatment, Probiotic Action explains how using probiotics for acne may help reduce the effects of body pain, and inflammation. Miami, FL (PRWEB) May 20, 2013 Researchers from the Southern University of Denmark have released informat...

XenoPort to drop multiple sclerosis drug after trial failure

(Reuters) - XenoPort Inc said it will stop developing its experimental multiple sclerosis treatment after data from a late-stage trial showed the drug did not improve patients' condition significantly compared with a placebo.

FDA Expands Alert About Lack of Sterility Assurance of NuVision Pharmacys Sterile Drug Products

The Food and Drug Administration (FDA) is alerting healthcare providers of concerns about a lack of sterility assurance of all sterile drug products made and distributed by NuVision Pharmacy of Dallas. The FDA recommends that these products should not be administered to patients. If a drug product marketed as sterile has microbial contamination,

AB SCIEX Announces In Vitro Diagnostic Devices CE Marked for Europe

Company to meet European regulatory requirements for use in clinical laboratories and hospitals AB SCIEX, a global leader in analytical technologies, today announced the launch of the 3200MD CE-IVDD series for general in vitro diagnostic use in Europe. Meeting regulatory requirements to obtain the CE-IVDD mark for the new AB SCIEX API 3...

Impax Laboratories to Present at the UBS Global Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel. Individuals may listen to the live or an archived presentation made at the conference, which will be post...

FDA has safety concerns on Merck insomnia drug

Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

UPDATE 1-XenoPort to drop multiple sclerosis drug after trial failure

May 20 (Reuters) - XenoPort Inc said it will stop developing its experimental multiple sclerosis treatment after data from a late-stage trial showed the drug did not improve patients' condition significantly compared with a placebo.

CVS/pharmacy® Reminds Patients with Diabetes about the Importance of Regular Testing to Help Manage Their Disease

WOONSOCKET, R.I., May 20, 2013 /PRNewswire/ -- CVS/pharmacy is reminding patients with diabetes that one of the most important ways they can manage their disease is to perform regular testing of their blood sugar (glucose) levels. While the number of providers that will accept Medicare coverage for diabetes testing supplies is expected to decline after July 1, 2013 due to Medicare changes, CV...

Proteomics Market - Mass Spectrometry & Biochips 2017 Forecast & Analysis in New Research Report at ReportsnReports.com

“Proteomics: Technologies and Global Markets” is the new market research report added to ReportsnReports.com store. Dallas, Texas (PRWEB) May 20, 2013 The main objective for the present report is to present the up-to-date market picture for proteomics into a single comprehensive report. The objective was to capture the changing industry dynamics and market shift occurring in this industry....

Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation for Early Onset LAL Deficiency from the U.S. Food and Drug Administration

Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to sebelipase alfa for the treatment of early onset lysosomal acid lipase deficiency (LAL Deficiency), also known a...

Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage Strengths

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 8,440,703 (“the ‘703 patent”) entitled “Methods of Using Sustained Release Aminopyridine Compositions.” The ‘703 patent includes claims directed to methods of improving lower extremity function and...

Apex Affinity Selects Elsevier's Gold Standard Drug Database

TAMPA, Florida, May 20, 2013 /PRNewswire/ -- Elsevier will provide Apex with essential drug information in a streamlined database solution Elsevier, a world-leading provider of scientific, medical and technical information products and services, today announced an agreement with Apex Affinity, provider of innovative prescription discount programs for uninsured and underinsured families nationwid...

Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)

CHAPEL HILL, N.C., May 20, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it presented data at the American Thoracic Society International Conference (ATS 2013) in Philadelphia demonstrating the antibacterial and e...

Elsevier Announces Collaboration with The Geological Society of America To Add Over 60,000 Maps to Geofacets Research Tool

NEW YORK, May 20, 2013 /PRNewswire/ -- Addition of maps from prestigious journals and books dating back to 1934 brings total number of Geofacets maps to over 300,000 Elsevier, a world-leading provider of scientific, medical and technical information products and services, today announced its collaboration with The Geological Society of America (GSA), one of the largest and most prestigious socie...

BioRestorative Therapies Signs Agreement with Dexterity, Inc. to Advance Production of the Company's Novel brtxDISC™ Stem Cell Therapy Device

JUPITER, Fla., May 20, 2013  /PRNewswire/ -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announces the signing of a consulting agreement with Dexterity, Inc. ("Dexterity"). Dexterity is a product design and bioengineering firm that will pro...

BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute

ROCKVILLE, Md. and BALTIMORE, May 20, 2013 /PRNewswire/ -- BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, today announced its selection of Ram Aiyar, Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) for BHI at the National...

Rosetta Genomics Announces Credentialing Agreement with Prime Health Services for miRview mets2

PHILADELPHIA and REHOVOT, Israel, May 20, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed a credentialing agreement with Prime Health Services, Inc. (Prime Health), a managed care company that offers a full spectrum of services, including a Preferred...

Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth

NEW YORK, LONDON, BERLIN and PARIS, May 20, 2013 /PRNewswire/ -- Arthroscopy Devices Market to 2018 - Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Future Growth" looks at the market landscape, competitive landscape, and market trends for the six arthroscopy device market segments: arthroscopes, arthroscopy shavers, arthroscopy Fluid Management...

Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer

WOBURN, Mass., May 20, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc. today announced the addition of Frederick W. Driscoll to its management team as chief financial officer. Mr. Driscoll has more than 30 years of financial management experience with biotechnology and medical device companies. Prior to joining Flexion, Mr. Driscoll was chief financial officer for Novavax (NASDAQ: NVAX) wher...

eFFECTOR Therapeutics Raises $45 Million in Series A Financing

SAN DIEGO, May 20, 2013 /PRNewswire/ -- eFFECTOR Therapeutics, a newly established biopharmaceutical company, today announced the completion of a $45 million Series A financing.  eFFECTOR is focused on inventing and developing small molecule drugs to selectively regulate protein synthesis, also known as translation, with an initial emphasis on cancer.  Series A investors include U.S. Ven...

Community Oncology Organizations, Clinics and Patients Support the Bipartisan "Preserve Community Cancer Care Act"

WASHINGTON, May 20, 2013 /PRNewswire/ -- A majority of cancer patients receive their treatment at community clinics. Today, that care is being threatened by a payment calculation in Medicare that has made it increasingly difficult for local clinics to absorb the additional cuts imposed by sequestration. Bipartisan legislation (S. 806) introduced by Senators Pat Roberts (R-KS) and Debbie...